相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Optimization of Multimeric Human Papillomavirus L2 Vaccines
Subhashini Jagu et al.
PLOS ONE (2013)
A Human Papillomavirus (HPV) In Vitro Neutralization Assay That Recapitulates the In Vitro Process of Infection Provides a Sensitive Measure of HPV L2 Infection-Inhibiting Antibodies
Patricia M. Day et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
Talia Malagon et al.
LANCET INFECTIOUS DISEASES (2012)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler et al.
LANCET ONCOLOGY (2012)
Incidence and Human Papillomavirus (HPV) Type Distribution of Genital Warts in a Multinational Cohort of Men: The HPV in Men Study
Gabriella M. Anic et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Cross-Neutralization Potential of Native Human Papillomavirus N-Terminal L2 Epitopes
Michael J. Conway et al.
PLOS ONE (2011)
The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies
Ivonne Rubio et al.
VIROLOGY (2011)
Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
Rolando Herrero et al.
CANCER DISCOVERY (2011)
In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection
Patricia M. Day et al.
CELL HOST & MICROBE (2010)
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
Hans-Ulrich Bernard et al.
VIROLOGY (2010)
Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes
Hsu-Kun Wang et al.
GENES & DEVELOPMENT (2009)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
Darron R. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines
Subhashini Jagu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2
Hannah H. Alphs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A protective and broadly cross-neutralizing epitope of human papillomavirus L2
Ratish Gambhira et al.
JOURNAL OF VIROLOGY (2007)
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2
Ratish Gambhira et al.
JOURNAL OF VIROLOGY (2007)
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection - A randomized trial
Allan Hildesheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan
Jeffrey N. Roberts et al.
NATURE MEDICINE (2007)
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
L. L. Villa et al.
BRITISH JOURNAL OF CANCER (2006)
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species
Ratish Gambhira et al.
CANCER RESEARCH (2006)
How will HPV vaccines affect cervical cancer?
Richard Roden et al.
NATURE REVIEWS CANCER (2006)
HPV vaccines in immunocompromised women and men
Joel M. Palefsky et al.
VACCINE (2006)
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2
DV Pastrana et al.
VIROLOGY (2005)
Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins
ME Embers et al.
VACCINE (2004)
Against which human papillomavirus types shall we vaccinate and screen?: The international perspective
N Muñoz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine
A de Jong et al.
VACCINE (2002)
Infectious virions produced from a human papillomavirus type 18/16 genomic DNA chimera
C Meyers et al.
JOURNAL OF VIROLOGY (2002)
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
RBS Roden et al.
VIROLOGY (2000)
分享论文
